



Canadian
Cancer Clinical
Trials Network

Réseau canadien
d'essais cliniques
sur le cancer

Canadian Cancer Clinical Trials Network

3CTN Y7Q1 Performance Report

April 1, 2020 – June 30, 2020


Table of Contents

Section A: Patient Access and Recruitment to the 3CTN Portfolio Trials.....	2
Patient Recruitment at All Network Sites.....	2
Portfolio Trials and Accruals by Region/Site.....	3
Patients recruited to 3CTN Portfolio trials, FY2019/20 (Y6) – BC, Alberta and Manitoba	3
Number of active recruiting 3CTN Portfolio trials – BC, Alberta and Manitoba	4
Patients recruited to 3CTN Portfolio trials, FY2019/20 (Y6) – Ontario	5
Number of active recruiting 3CTN Portfolio trials – Ontario	6
Patients recruited to 3CTN Portfolio trials, FY2019/20 (Y6) – Atlantic Region and Quebec	7
Number of active recruiting 3CTN Portfolio Trials – Atlantic Region and Quebec	8
Section B: 3CTN Portfolio Metrics	9
Active Recruiting Portfolio Trials by Disease Site and Phase.....	9
Portfolio Impact Assessment.....	10
Overview of Portfolio Applications – Process Efficiency	11
Trials Added to the 3CTN Portfolio in Y7 (April-Sept 23, 2020)	12

Section A: Patient Access and Recruitment to the 3CTN Portfolio Trials

Patient Recruitment at All Network Sites

Objective: To improve patient access to academic clinical trials and improve patient recruitment by greater than 75% within four years.



Notes:

- 3CTN network adult sites' Y7Q1 recruitment is 73% lower than that for the previous year due to COVID-19 impacts at cancer centres across Canada.
- 339 patients were recruited to Portfolio trials in Quarter 1. Y7 target is to achieve 65% above pre-3CTN baseline.
- Overall, ~14% of Adult Sites (6 out of 42) are on track to meet their Y7 target.
- *Nova Scotia's Y7Q1 recruitment was unreported.
- ** Pediatric progress to pre-3CTN baseline recruitment is shown. 3 Pediatric sites are on track to exceed their pre-3CTN baseline by end of Y7.

Portfolio Trials and Accruals by Region/Site

Patients recruited to 3CTN Portfolio trials, FY2019/20 (Y6) – BC, Alberta and Manitoba

Network Site	Pre-3CTN Baseline	Y2 Total	Y3 Total	Y4 Total	Y5 Total	Y6 Total	Year 7 (2020-21)			
							Q1	Total	% of Baseline	% to Target*
CancerCare Manitoba	99	72	102	90	98	51	3	3	3%	2%
Western Manitoba Cancer Centre	1	0	0	0	1	1	0	0	0%	0%
CancerCare Manitoba - Pediatrics	18	20	14	17	4	7	4	4	22%	-
Manitoba Total	118	92	116	107	103	59	7	7	6%	2%
BC Cancer – Vancouver	106	117	152	127	107	110	16	16	15%	9%
BC Cancer – Abbotsford	16	28	14	22	22	1	1	1	6%	4%
BC Cancer – Prince George	1	6	4	8	9	10	2	2	200%	121%
BC Cancer – Kelowna	38	40	30	28	38	33	11	11	29%	18%
BC Cancer – Victoria	26	44	69	64	69	78	4	4	15%	9%
British Columbia Total	187	235	269	249	245	232	34	34	18%	11%
Cross Cancer Institute	102	112	137	99	103	310	32	32	31%	19%
Tom Baker Cancer Centre	76	140	125	154	139	341	19	19	25%	15%
Alberta Total	178	252	262	253	242	651	51	51	29%	17%
Western Region Total	483	579	647	609	590	942	92	92	19%	11%

* Pediatric sites are excluded in province and regional “% to Y7 Target” calculations

Number of active recruiting 3CTN Portfolio trials – BC, Alberta and Manitoba

Network Site	Pre-3CTN Baseline	Y5 (2018-19)				Y6 (2019-20)				Y7 (2020-21)
		Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1
CancerCare Manitoba	37	28	27	29	23	22	19	16	22	13
Western Manitoba Cancer Centre	0	0	0	1	1	1	1	1	1	1
CancerCare Manitoba - Pediatrics	19	17	17	15	13	10	9	8	9	9
BC Cancer – Vancouver	50	25	25	27	27	26	25	23	27	16
BC Cancer – Abbotsford	6	4	4	4	4	5	5	0	0	1
BC Cancer – Prince George	2	3	3	3	3	2	2	3	3	4
BC Cancer – Kelowna	23	9	10	6	6	5	5	5	7	4
BC Cancer – Victoria	12	5	6	5	5	8	7	6	6	7
Cross Cancer Institute	29	29	28	30	29	27	26	27	21	14
Tom Baker Cancer Centre	20	29	32	32	30	30	34	33	33	28

Note: COVID-19 caused a majority of sites and sponsors to put their trial setup or recruitment on hold during Y7Q1.

Patients recruited to 3CTN Portfolio trials, FY2019/20 (Y6) – Ontario

Network Site	Pre-3CTN Baseline	Y2 Total	Y3 Total	Y4 Total	Y5 Total	Y6 Total	Year 7 (2020-21)			
							Q1	Total	% of Baseline	% to Target
London Health Sciences Centre	186	172	187	169	248	942	39	39	21%	13%
Grand River Regional Cancer Centre	20	13	43	32	34	19	9	9	45%	27%
Windsor Regional Cancer Centre	14	17	63	32	16	3	0	0	0%	0%
Juravinski Cancer Centre	181	231	247	454	345	217	16	16	9%	5%
Cambridge Memorial Hospital	11	2	5	4	5	8	3	3	27%	17%
St. Joseph's Healthcare Hamilton	21	30	54	74	40	20	6	6	29%	17%
Walker Family Cancer Centre	17	22	13	23	37	40	1	1	6%	4%
Sunnybrook Health Sciences Centre	141	229	398	363	651	638	27	27	19%	12%
Humber River Hospital	1	2	1	9	7	3	1	1	100%	61%
Michael Garron Hospital	2	2	1	7	2	0	0	0	0%	0%
Princess Margaret Cancer Centre	396	384	533	473	720	543	14	14	4%	2%
Markham Stouffville Hospital	1	0	28	9	2	6	0	0	0%	0%
Mount Sinai Hospital	21	12	40	7	12	7	0	0	0%	0%
Northeast Cancer Centre	24	17	12	9	18	17	0	0	0%	0%
North York General Hospital	1	4	8	11	9	7	0	0	0%	0%
Royal Victoria Regional Health Centre	8	18	58	23	9	25	4	4	50%	30%
St. Michael's Hospital	19	0	27	2	1	3	0	0	0%	0%
Southlake Regional Health Centre	10	15	75	26	68	32	1	1	10%	6%
Thunder Bay Regional Health Sciences Centre	26	3	46	16	25	4	0	0	0%	0%
Trillium Health Partners - Credit Valley Hospital	27	5	51	10	12	10	0	0	0%	0%
William Osler Health System	1	0	29	13	0	16	0	0	0%	0%
The Ottawa Hospital Cancer Centre	132	238	396	500	850	804	62	62	47%	28%
Cancer Centre of Southeastern Ontario at Kingston General Hospital	41	58	122	84	72	89	17	17	41%	25%
R.S. McLaughlin Durham Regional Cancer Centre	22	26	70	18	15	36	0	0	0%	0%
Central Region Total	1323	1500	2507	2368	3198	3489	200	200	15%	9%

Number of active recruiting 3CTN Portfolio trials – Ontario

Network Site	Pre-3CTN Baseline	Y5 (2018-19)				Y6 (2019-20)				Y7 (2020-21)
		Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1
London Health Sciences Centre	79	45	46	46	40	47	52	54	57	45
Grand River Regional Cancer Centre	11	8	8	8	8	6	7	8	8	8
Windsor Regional Cancer Centre	4	4	4	5	5	4	4	4	3	4
Juravinski Cancer Centre	51	29	27	30	32	22	26	24	34	13
Cambridge Memorial Hospital	5	2	2	3	2	2	2	2	2	2
St. Joseph's Healthcare Hamilton	2	3	2	2	3	1	1	1	1	1
Walker Family Cancer Centre	10	8	7	8	7	6	6	8	7	8
Sunnybrook Health Sciences Centre	10	32	34	34	35	34	36	36	35	47
Humber River Hospital	0	3	3	2	2	2	2	3	2	3
Michael Garron Hospital	3	2	2	2	2	1	1	1	1	1
Princess Margaret Cancer Centre	91	71	74	81	86	78	88	89	80	80
Markham Stouffville Hospital	0	0	0	1	1	1	0	1	1	1
Mount Sinai Hospital	6	4	4	4	4	4	5	6	3	3
Northeast Cancer Centre	10	6	7	7	8	7	7	7	7	8
North York General Hospital	0	3	4	3	3	3	5	4	1	2
Royal Victoria Regional Health Centre	5	8	6	6	6	6	6	9	10	10
St. Michael's Hospital	4	1	1	1	2	2	2	3	2	2
Southlake Regional Health Centre	3	9	10	10	10	9	8	8	7	6
Thunder Bay Regional Health Sciences Centre	8	5	5	5	5	5	5	4	3	0
Trillium Health Partners - Credit Valley Hospital	9	3	3	3	4	4	4	3	6	0
William Osler Health System	0	1	1	2	2	1	2	2	2	1
The Ottawa Hospital Cancer Centre	56	38	37	41	51	41	36	34	15	10
Cancer Centre of Southeastern Ontario at Kingston General Hospital	18	26	25	25	26	21	33	33	22	21
R.S. McLaughlin Durham Regional Cancer Centre	13	3	4	3	3	3	3	2	2	0

Note: COVID-19 caused a majority of sites and sponsors to put their trial setup or recruitment on hold during Y7Q1.

Patients recruited to 3CTN Portfolio trials, FY2019/20 (Y6) – Atlantic Region and Quebec

Network Site	Pre-3CTN Baseline	Y2 Total	Y3 Total	Y4 Total	Y5 Total	Y6 Total	Year 7 (2020-21)			
							Q1	Total	% of Baseline	% to Target*
Nova Scotia Health Authority	39	40	52	45	42	20	DNR	DNR	DNR	DNR
Eastern Regional Health Authority	15	4	12	8	15	16	0	0	0%	0%
Janeway Children's Health and Rehabilitation Centre	4	3	4	4	0	0	3	3	75%	-
Atlantic Total	58	47	68	57	57	36	3	3	5%	0%
CIUSSS du Centre-Ouest-de-l'Île-de-Montréal (CIUSSS CODIM)	87	76	161	149	71	155	9	9	10%	6%
CISSS de l'Outaouais	3	0	4	32	1	5	0	0	0%	0%
CHU de Québec – Université Laval, adults	180	25	144	236	99	309	14	14	8%	5%
CIUSSS de l'Estrie – Centre hospitalier universitaire de Sherbrooke, adults (CIUSSS-Estrie-CHUS)	46	16	70	55	18	61	0	0	0%	0%
Centre Hospitalier de l'Université de Montréal (CHUM)	153	59	123	149	112	66	2	2	1%	1%
CIUSSS du Nord-de-l'Île-de-Montréal (CIUSSS NDIM)	3	0	4	16	8	539	0	0	0%	0%
CIUSSS de l'Est-de-l'Île-de-Montréal (CIUSSS EDIM)	60	12	51	49	23	15	0	0	0%	0%
CHU de Québec-Université Laval / Centre Mère-Enfant Soleil	17	14	7	17	22	21	8	8	47%	-
Centre hospitalier universitaire de Sainte-Justine	42	26	44	40	38	38	10	10	24%	-
Montreal Children's Hospital	24	23	14	20	8	10	1	1	4%	-
Quebec Total	615	251	622	763	400	1219	44	44	7%	3%
Eastern Region Total	673	298	690	820	457	1255	47	47	7%	3%

* Pediatric sites are excluded in province and regional “% to Y7 Target” calculations.

DNR= Did Not Report

Number of active recruiting 3CTN Portfolio Trials – Atlantic Region and Quebec


Network Site	Pre-3CTN Baseline	Y5 (2018-19)				Y6 (2019-20)				Y7 (2020-21)
		Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1
Nova Scotia Health Authority	14	12	16	17	17	19	14	17	16	DNR
Eastern Regional Health Authority	6	4	6	5	6	8	9	10	9	0
Janeway Children's Health and Rehabilitation Centre	5	11	9	9	9	5	9	6	6	7
CIUSSS du Centre-Ouest-de-l'Île-de-Montréal (CIUSSS CODIM)	27	N/A	N/A	N/A	N/A	18	15	24	17	17
CISSS de l'Outaouais	1	1	1	1	2	2	2	2	2	2
CHU de Québec – Université Laval, adults	39	19	20	26	26	26	26	25	30	27
CIUSSS de l'Estrie – Centre hospitalier universitaire de Sherbrooke, adults (CIUSSS-Estrie-CHUS)	10	13	11	13	16	14	15	17	17	16
Centre Hospitalier de l'Université de Montréal (CHUM)	28	32	34	37	37	33	30	33	30	27
CIUSSS du Nord-de-l'Île-de-Montréal (CIUSSS NDIM)	4	2	2	2	2	2	3	3	2	0
CIUSSS de l'Est-de-l'Île-de-Montréal (CIUSSS EDIM)	6	12	13	11	10	10	8	11	10	9
CHU de Québec-Université Laval / Centre Mère-Enfant Soleil	11	13	16	17	15	17	15	13	11	15
Centre hospitalier universitaire de Sainte-Justine	9	30	22	22	24	17	18	18	17	17
Montreal Children's Hospital	5	25	25	20	21	12	16	16	13	16

Note: COVID-19 caused a majority of sites and sponsors to put their trial setup or recruitment on hold during Y7Q1.

Section B: 3CTN Portfolio Metrics

Active Recruiting Portfolio Trials by Disease Site and Phase

Objective: To monitor and optimize the Portfolio in order to create opportunities for new trials and demonstrate 3CTN's impact.



Portfolio Impact Assessment

Objective: To provide a more specific and translatable impact description of 3CTN Portfolio trials for existing and future stakeholders.

Trial Categories of Interest	Breakthrough	Platform	Enhancement/ derivative	Cross cancer	Sustaining	N/A	Total # of Trials per Study Criteria
Novel therapy	9	9	6	2	-	-	24
Rare cancer setting	2	28	9	1	7	1	47
Vulnerable populations	-	19	5	1	7	-	31
Precision medicine	6	39	17	4	5	2	69
Patient management	1	43	5	7	22	4	75
Lifestyle Interventions	-	7	-	-	-	-	7
N/A	-	8	1	-	-	-	9
Total # of Trials per Study Criteria	9	103	20	11	28	4	164

Note: A trial may fit into more than one categories; N=164 is the unique count of reviewed trials that were active at any point in Y7 (2020-21).

To see the complete Impact Analysis of the Portfolio click [here](#)

Overview of Portfolio Applications – Process Efficiency

Objective: To improve Portfolio application processing time.

Portfolio Approval Process Timeline¹

Calendar Year	Number of Applications Received	# Applications Completed	Average Application Processing Time (days)	Median Application Processing Time (days)
2015	90	85	16	7
2016	70	71	31	6
2017	45	47	22	6
2018	46	44	18	5
2019	45	45	42	3
2020 (Jan – Sept)	26	28	30	0

Facilitated Peer Review (FPR) Process

Calendar Year	Number of FPR Requests	# FPR Completed ²	Average FPR Time (days) ³	Median FPR Time (days) ³
2015	6	3	47	39
2016	11	12	96	100
2017	4	5	79	74
2018	10	7	84	77
2019	16	17	112	86
2020 (Jan – Sept)	2	5	96	97

¹ From application received to approve/decline the application for period, Jan 13, 2015 to Sept 14, 2020.

² Counts are based on the completed applications in that calendar year, e.g. for an application submitted for review in 2019 but completed the review process in 2020, the FPR time will be used for the 2020 calculation.

³ FPR process time is from the start date of peer review (i.e. site agreed to pursue peer review) to the date the last reviewer package is submitted to 3CTN (completed trials only).

Additional link to interactive Portfolio Application report: [Portfolio Applications Report](#)

Trials Added to the 3CTN Portfolio in Y7 (April 1-Sept 23, 2020)

Trial short title	Trial phase	Disease site	Complexity rating	Canadian trial status	Trial link
(CCTG) CEC.7/ALLIANCE A071801	Phase III	Brain/CNS	Standard	Open to recruitment	NCT04114981
(GCAR) GBM AGILE	Phase II/III	Brain/CNS	Standard	Project in Setup	NCT03970447
COG - ACNS1721	Phase II	Brain/CNS	High	Open to recruitment	NCT03581292
COG - ANBL1821/Relapsed NBL DFMO	Phase II	Brain/CNS	High	Suspended/On hold	NCT03794349
(BCC) BRLALEAST	Phase II	Breast	Standard	Open to recruitment	NCT03917082
(BCC) CARA/ H19-03343	Phase III	Breast	Low	Open to recruitment	NCT04257396
(CCTG) CRC.9 / NRG-GI005	Phase II/III	Gastrointestinal	Standard	Open to recruitment	NCT04068103
(BCC) PROTRACT Study	Phase II	Genito-Urinary	Standard	Open, not yet recruiting	NCT04015622
(CCTG) IND.234G/PC-BETS Sub-Study G	Phase II	Genito-Urinary	Standard	Open to recruitment	NCT03385655
OCOG - 2019-CYTOSHRINK / CA209-7DR	Phase II	Genito-Urinary	High	Open to recruitment	NCT04090710
(CCTG) CX.6/ SENTICOL III	Not Applicable	Gynecological	Low	Open to recruitment	NCT03386734
COG - AALL1731	Phase III	Hematology	High	Open to recruitment	NCT03914625
COG - AALL1732	Phase III	Hematology	High	Open to recruitment	NCT03959085
(CCTG) BRC.8/ SWOG S1827/ MAVERICK	Phase III	Lung	Low	Open to recruitment	NCT04155034
(CCTG) IC.8	Phase III	Other	Low	Open to recruitment	NCT04442048
(UHN) SMARTCare	Not Applicable	Other	Low	Open to recruitment	NCT03849950
COG - ACCL1633	Phase III	Other	Low	Open to recruitment	NCT03057054
(CCTG) ME.15	Phase III	Skin / Melanoma	Low	Open, not yet recruiting	NCT03860883